Green Thumb Industries Inc.

CNSX:GTII Stock Report

Market Cap: CA$3.0b

Green Thumb Industries Valuation

Is GTII undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GTII when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GTII (CA$12.68) is trading below our estimate of fair value (CA$54.76)

Significantly Below Fair Value: GTII is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GTII?

Key metric: As GTII is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GTII. This is calculated by dividing GTII's market cap by their current earnings.
What is GTII's PE Ratio?
PE Ratio33.7x
EarningsUS$63.62m
Market CapUS$2.15b

Price to Earnings Ratio vs Peers

How does GTII's PE Ratio compare to its peers?

The above table shows the PE ratio for GTII vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23.3x
CPH Cipher Pharmaceuticals
17.2x12.7%CA$380.3m
RX BioSyent
18.4xn/aCA$130.4m
GRIN Grown Rogue International
38.8xn/aCA$208.9m
MDP Medexus Pharmaceuticals
18.8x49.9%CA$60.4m
GTII Green Thumb Industries
33.7x33.2%CA$3.0b

Price-To-Earnings vs Peers: GTII is expensive based on its Price-To-Earnings Ratio (33.7x) compared to the peer average (23.3x).

Price to Earnings Ratio vs Industry

How does GTII's PE Ratio compare vs other companies in the North American Pharmaceuticals Industry?

13 CompaniesPrice / EarningsEstimated GrowthMarket Cap
GTII 33.7xIndustry Avg. 18.8xNo. of Companies13PE01224364860+
13 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: GTII is expensive based on its Price-To-Earnings Ratio (33.7x) compared to the North American Pharmaceuticals industry average (18.8x).

Price to Earnings Ratio vs Fair Ratio

What is GTII's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GTII PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio33.7x
Fair PE Ratio36x

Price-To-Earnings vs Fair Ratio: GTII is good value based on its Price-To-Earnings Ratio (33.7x) compared to the estimated Fair Price-To-Earnings Ratio (36x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GTII forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$12.68
CA$22.93
+80.8%
19.5%CA$31.28CA$17.11n/a9
Nov ’25CA$14.36
CA$26.61
+85.3%
16.2%CA$35.74CA$22.78n/a9
Oct ’25CA$13.97
CA$25.89
+85.4%
15.4%CA$34.89CA$22.24n/a10
Sep ’25CA$12.95
CA$28.21
+117.9%
26.3%CA$47.87CA$22.43n/a11
Aug ’25CA$15.86
CA$28.56
+80.1%
26.2%CA$48.37CA$22.77n/a11
Jul ’25CA$16.50
CA$28.41
+72.2%
25.7%CA$47.77CA$22.49n/a11
Jun ’25CA$15.50
CA$27.10
+74.8%
26.9%CA$47.75CA$18.10n/a13
May ’25CA$18.41
CA$26.39
+43.3%
24.4%CA$45.88CA$18.26n/a13
Apr ’25CA$20.31
CA$25.05
+23.3%
14.5%CA$32.02CA$18.05n/a13
Mar ’25CA$17.70
CA$25.09
+41.7%
17.6%CA$35.96CA$17.98n/a13
Feb ’25CA$18.53
CA$22.86
+23.4%
22.7%CA$35.15CA$14.61n/a13
Jan ’25CA$14.87
CA$22.13
+48.8%
24.4%CA$35.11CA$14.60n/a13
Dec ’24CA$14.17
CA$22.42
+58.2%
24.5%CA$35.63CA$14.81n/a13
Nov ’24CA$11.36
CA$23.97
+111.0%
26.3%CA$38.91CA$15.46CA$14.3611
Oct ’24CA$15.00
CA$23.61
+57.4%
26.0%CA$38.13CA$15.15CA$13.9711
Sep ’24CA$12.81
CA$23.37
+82.5%
25.0%CA$37.94CA$15.08CA$12.9512
Aug ’24CA$9.40
CA$25.42
+170.4%
29.0%CA$45.98CA$16.63CA$15.8612
Jul ’24CA$10.04
CA$24.54
+144.4%
33.1%CA$45.51CA$10.71CA$16.5013
Jun ’24CA$9.95
CA$24.57
+146.9%
34.1%CA$46.74CA$11.00CA$15.5012
May ’24CA$9.93
CA$27.01
+172.0%
42.4%CA$60.70CA$12.93CA$18.4113
Apr ’24CA$10.27
CA$27.43
+167.1%
40.8%CA$61.54CA$13.11CA$20.3114
Mar ’24CA$11.20
CA$28.05
+150.5%
37.8%CA$60.92CA$16.98CA$17.7014
Feb ’24CA$11.05
CA$30.62
+177.1%
34.2%CA$59.95CA$15.72CA$18.5314
Jan ’24CA$11.98
CA$30.09
+151.2%
34.1%CA$58.89CA$15.45CA$14.8714
Dec ’23CA$19.51
CA$30.09
+54.2%
34.1%CA$58.89CA$15.45CA$14.1714
Nov ’23CA$16.03
CA$33.11
+106.6%
36.7%CA$57.58CA$15.80CA$11.3614

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Medexus Pharmaceuticals

CA$60.4m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.45

7D

9.4%

1Y

69.0%

Verano Holdings

CA$722.2m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.02

7D

-15.5%

1Y

-65.2%

Fennec Pharmaceuticals

US$145.9m

Operates as a biopharmaceutical company in the United States.

FRX

US$7.35

7D

29.4%

1Y

-35.8%